Hypertensive Ambulatory Trial to Compare the Efficacy of HCTZ and Lisinopril (1HAT)
|ClinicalTrials.gov Identifier: NCT01258764|
Recruitment Status : Completed
First Posted : December 13, 2010
Last Update Posted : May 20, 2015
|Condition or disease||Intervention/treatment|
|Hypertension, Grade 1 Hypertension Treatment N of 1 Study Design Hypertension||Drug: Lisinopril Drug: Hydrochlorothiazide|
Personalized medicine involves choosing the optimal treatment for a patient based on data gathered by the physician that is specific to that individual. The N-of-1 or single patient trial is a study design motivated by the new era of personalized medicine. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommends a personalized medicine approach to hypertensive drug class choice based on compelling indications. However, the hypertensive decision algorithm is limited. With the advent of new technology the amount of data available to a physician has grown substantially improving the robustness of surveying a more complete picture of the patient's health care status. Medicine is quickly becoming data intensive with new technology decreasing the cost of data collection and analysis.
The typical standard care for patients with stage 1 hypertension first involves a non-pharmacological modification of lifestyle changes. Health care providers diagnose hypertension when the blood pressure is persistently elevated after three to six visits over a several month period. JNC 7 recommends thiazide-type diuretics for Stage I hypertension for most patients. In the United States, this recommendation results in most patients being given a dose of hydrochlorothiazide (HCTZ) at 12.5 to 25 mg per day. A patient would then return for follow-up and would be prescribed a few month supply of an antihypertensive medication (e.g. HCTZ or lisinopril). The choice of treatment by the physician is based on JNC 7 guidelines, patient's risk factors, and a provider's experience.
The objective of this trial will be to evaluate if an objective clinical decision of anti-hypertensive therapy can be made using an N-of-1 (single patient) trial design. In this study we propose to do a series of N-of-1 trials in patients with stage 1 hypertension who will be randomized to alternating courses of HCTZ and lisinopril.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Series of Single Patient Trials Comparing the Efficacy Between the Most Commonly Prescribed Thiazide Diuretic in the US, Hydrochlorothiazide, and Lisinopril for the Treatment of Stage 1 Hypertension.|
|Study Start Date :||November 2010|
|Primary Completion Date :||March 2014|
|Study Completion Date :||March 2014|
|Active Comparator: Lisinopril||
Lisinopril 10 mg oral, once daily for four week cycle and a 2 week cycle
|Active Comparator: Hydrochlorothiazide||
Hydrochlorothiazide 25 mg oral, once daily for 4 week cycle and a 2 week cycle
- Blood pressure control defined as 24-hour ambulatory systolic and diastolic pressure average below 135/85 mmHg. [ Time Frame: After 14 week study period with assessment of patient specific data ]
- Blood Pressure (BP) load, treatment of non-dippers, side effects, and compliance. [ Time Frame: After 14 week study period with assessment of patient specific data ]BP load is defined as the percentage of ambulatory systolic and diastolic pressure exceeding 140 mmHg and 90 mmHg during the daytime and 120 mmHg and 80 mmHg during sleep. Systolic BP load averages 9-25% depending on age. While diastolic BP load averages 3-4%. Failure of BP to fall by at least 10 percent during sleep will define a non-dipper. Extreme dipping will be defined by a nocturnal BP decline of greater than 20 percent with a large morning increase in BP.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01258764
|United States, California|
|La Jolla, California, United States, 92037|
|Principal Investigator:||Bradley Patay, MD||Scripps Clinic|